New pill targets Cancer's genetic weakness in first human trial
NCT ID NCT07038369
Summary
This is a first-in-human study to find a safe dose and see how the body processes a new oral drug called ATV-1601. It is being tested in adults with advanced solid tumors, including certain breast cancers, that have a specific genetic change called an AKT1 E17K mutation. The main goals are to check for side effects and determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Florida Cancer Specialists & Research Institute - Lake Mary
Lake Mary, Florida, 32746, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
START Madrid - CIOCC
Madrid, 28050, Spain
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.